MX2008015254A - Uso terapeutico que es simultaneo, separado o secuencial de al menos una neurotoxina de botulinum, y de al menos un derivado opiaceo. - Google Patents
Uso terapeutico que es simultaneo, separado o secuencial de al menos una neurotoxina de botulinum, y de al menos un derivado opiaceo.Info
- Publication number
- MX2008015254A MX2008015254A MX2008015254A MX2008015254A MX2008015254A MX 2008015254 A MX2008015254 A MX 2008015254A MX 2008015254 A MX2008015254 A MX 2008015254A MX 2008015254 A MX2008015254 A MX 2008015254A MX 2008015254 A MX2008015254 A MX 2008015254A
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum neurotoxin
- simultaneous
- separate
- therapeutic use
- opiate derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
Abstract
La presente invención se refiere a una composición que comprende: al menos una neurotoxina botulínica, y al menos un derivado opiáceo o su sal. La invención también se refiere a un producto que comprende al menos una neurotoxina botulínica y al menos un derivado opiáceo o su sal, como un producto en combinación para el uso terapéutico o simultáneo, secuencial o separado en el tratamiento o prevención del dolor y de trastornos neuromusculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0605368A FR2902341B1 (fr) | 2006-06-16 | 2006-06-16 | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
PCT/FR2007/000956 WO2007144493A2 (fr) | 2006-06-16 | 2007-06-11 | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008015254A true MX2008015254A (es) | 2008-12-17 |
Family
ID=37616909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008015254A MX2008015254A (es) | 2006-06-16 | 2007-06-11 | Uso terapeutico que es simultaneo, separado o secuencial de al menos una neurotoxina de botulinum, y de al menos un derivado opiaceo. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9080220B2 (es) |
EP (1) | EP2037956B1 (es) |
JP (1) | JP5425622B2 (es) |
CN (1) | CN101466401A (es) |
AU (1) | AU2007259122B2 (es) |
BR (1) | BRPI0713693A2 (es) |
CA (1) | CA2655488C (es) |
DK (1) | DK2037956T3 (es) |
ES (1) | ES2399661T3 (es) |
FR (1) | FR2902341B1 (es) |
HK (1) | HK1130011A1 (es) |
IL (1) | IL195254A (es) |
MX (1) | MX2008015254A (es) |
PL (1) | PL2037956T3 (es) |
PT (1) | PT2037956E (es) |
RU (1) | RU2434637C2 (es) |
WO (1) | WO2007144493A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
ES2356883B1 (es) * | 2008-07-24 | 2012-02-22 | Bcn Peptides, S.A. | Composición para el tratamiento del dolor y/o la inflamación. |
EP3372239B1 (en) | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
AU2014285058A1 (en) * | 2013-07-03 | 2016-02-18 | Toxcure, LLC | Reducing adverse side effects of a compound by a neurotoxin |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
JP2017526715A (ja) * | 2014-09-12 | 2017-09-14 | アラーガン、インコーポレイテッドAllergan,Incorporated | 変形性関節症の痛みの治療方法 |
US11268080B2 (en) | 2015-03-26 | 2022-03-08 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
EP3679946B1 (en) | 2016-05-27 | 2022-01-05 | Ipsen Biopharm Limited | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine |
WO2018039506A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
AU2018290765A1 (en) * | 2017-06-26 | 2020-01-23 | Bonti, Inc. | Clostridial neurotoxin formulations and use |
KR102088104B1 (ko) * | 2018-06-29 | 2020-03-11 | 호서대학교 산학협력단 | 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물 |
US20210393748A1 (en) | 2018-10-02 | 2021-12-23 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for treating lipoedema |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457916A (en) | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
EP1502600B1 (en) | 1993-12-28 | 2009-10-07 | Allergan, Inc. | Use of the neurotoxic component of botulinum toxin for treating smooth muscle disorders |
US6136551A (en) | 1995-04-24 | 2000-10-24 | Allergan, Inc. | Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
WO2001047512A2 (en) | 1999-12-08 | 2001-07-05 | Fluoro Probe, Inc. | Method for relieving pain associated with an internal disease site |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
BR0108173A (pt) * | 2000-02-08 | 2003-01-21 | Allergan Inc | Composições farmacêuticas de toxina de botulina |
US20060269575A1 (en) | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US20020192239A1 (en) | 2001-01-09 | 2002-12-19 | Borodic Gary E. | Use of botulinum toxin for the treatment of chronic facial pain |
KR20030018827A (ko) | 2001-08-31 | 2003-03-06 | 서구일 | A형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제 |
US7022329B2 (en) | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US20050152905A1 (en) | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
WO2004075832A2 (en) | 2003-02-27 | 2004-09-10 | Lucas John M | Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof |
WO2004084839A2 (en) | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
US7270287B2 (en) * | 2004-01-06 | 2007-09-18 | Allergan, Inc. | Botulinum toxin treatment for kinesia |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
GB2417419A (en) * | 2004-07-12 | 2006-03-01 | Ipsen Ltd | Therapeutic use of Botulinum toxin |
GB2416692A (en) | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
GB2419526A (en) * | 2004-10-28 | 2006-05-03 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
WO2006042249A2 (en) | 2004-10-08 | 2006-04-20 | Neuromolecular Pharmaceuticals, Inc. | Methods and compositions for treating migraine pain |
TW200621785A (en) | 2004-11-04 | 2006-07-01 | Toray Industries | Analgesic |
EP1863524A1 (en) | 2005-03-03 | 2007-12-12 | Universite Catholique De Louvain | Methods and compositions for the treatment of cancer |
US20090214466A1 (en) | 2005-05-09 | 2009-08-27 | Levin Bruce H | Methods of Alleviating Disorders and Their Associated Pain |
KR100726441B1 (ko) | 2005-11-22 | 2007-06-11 | 삼성전자주식회사 | 현상장치 및 이를 이용한 화상형성장치 |
FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
-
2006
- 2006-06-16 FR FR0605368A patent/FR2902341B1/fr not_active Expired - Fee Related
-
2007
- 2007-06-11 CN CNA2007800220160A patent/CN101466401A/zh active Pending
- 2007-06-11 EP EP07788861A patent/EP2037956B1/fr not_active Not-in-force
- 2007-06-11 US US12/305,191 patent/US9080220B2/en not_active Expired - Fee Related
- 2007-06-11 ES ES07788861T patent/ES2399661T3/es active Active
- 2007-06-11 BR BRPI0713693-5A patent/BRPI0713693A2/pt not_active Application Discontinuation
- 2007-06-11 MX MX2008015254A patent/MX2008015254A/es active IP Right Grant
- 2007-06-11 WO PCT/FR2007/000956 patent/WO2007144493A2/fr active Application Filing
- 2007-06-11 RU RU2009101152/15A patent/RU2434637C2/ru active
- 2007-06-11 DK DK07788861.8T patent/DK2037956T3/da active
- 2007-06-11 PL PL07788861T patent/PL2037956T3/pl unknown
- 2007-06-11 CA CA2655488A patent/CA2655488C/fr not_active Expired - Fee Related
- 2007-06-11 JP JP2009514842A patent/JP5425622B2/ja not_active Expired - Fee Related
- 2007-06-11 AU AU2007259122A patent/AU2007259122B2/en not_active Ceased
- 2007-06-11 PT PT77888618T patent/PT2037956E/pt unknown
-
2008
- 2008-11-12 IL IL195254A patent/IL195254A/en active IP Right Grant
-
2009
- 2009-09-02 HK HK09108027.1A patent/HK1130011A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2007144493A3 (fr) | 2008-04-17 |
US9080220B2 (en) | 2015-07-14 |
IL195254A0 (en) | 2011-08-01 |
FR2902341A1 (fr) | 2007-12-21 |
RU2009101152A (ru) | 2010-07-27 |
US20090232851A1 (en) | 2009-09-17 |
EP2037956A2 (fr) | 2009-03-25 |
PT2037956E (pt) | 2013-02-06 |
IL195254A (en) | 2012-03-29 |
HK1130011A1 (en) | 2009-12-18 |
AU2007259122A1 (en) | 2007-12-21 |
JP5425622B2 (ja) | 2014-02-26 |
AU2007259122B2 (en) | 2012-11-01 |
CA2655488C (fr) | 2016-11-01 |
BRPI0713693A2 (pt) | 2012-10-30 |
CA2655488A1 (fr) | 2007-12-21 |
RU2434637C2 (ru) | 2011-11-27 |
WO2007144493A2 (fr) | 2007-12-21 |
DK2037956T3 (da) | 2013-02-04 |
FR2902341B1 (fr) | 2011-02-25 |
EP2037956B1 (fr) | 2012-12-12 |
JP2009539948A (ja) | 2009-11-19 |
CN101466401A (zh) | 2009-06-24 |
PL2037956T3 (pl) | 2013-04-30 |
ES2399661T3 (es) | 2013-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1130011A1 (en) | Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative | |
TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
UA108198C2 (uk) | Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування | |
TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
CL2009000699A1 (es) | Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras. | |
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
ATE510538T1 (de) | Zusammensetzungen und verfahren für nervenschutz | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
WO2009045356A8 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
MY150602A (en) | Subtituted-quinoxaline-type piperidine compounds and the uses thereof | |
PL1910338T3 (pl) | Związki heterotetracykliczne jako mimetyki TPO | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
MX2008002166A (es) | Compuestos y composiciones como mimeticos de trombopoietina (tpo). | |
WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
WO2006020680A3 (en) | Heterocyclic compounds as pharmaceutical agents | |
JO2721B1 (en) | Derivatives of artemisia plant and its preparations and therapeutic applications | |
MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
MX2008011454A (es) | Uso novedoso de agentes antihistaminicos para el tratamiento preventivo o temprano de sindromes inflamatorios, en particular los que son accionados por togavirus. | |
MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status | ||
FG | Grant or registration |